---
document_datetime: 2025-12-02 04:51:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/voranigo.html
document_name: voranigo.html
version: success
processing_time: 0.1007805
conversion_datetime: 2025-12-27 14:08:37.447088
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Voranigo

[RSS](/en/individual-human-medicine.xml/263612)

##### Authorised

This medicine is authorised for use in the European Union

vorasidenib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Voranigo](#news-on)
- [More information on Voranigo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Voranigo is a cancer medicine used to treat cancers of the brain called astrocytoma or oligodendroglioma in adults and adolescents from 12 years of age who weigh at least 40 kg, have had surgery as their only treatment and do not need other treatments such as radiotherapy or chemotherapy immediately.

It is used for tumours that are mainly slow growing (grade 2) and when the cancer cells have specific changes in the genes (mutations) that make proteins known as isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2).

Voranigo contains the active substance vorasidenib.

Expand section

Collapse section

## How is Voranigo used?

The medicine can only be obtained with a prescription. Treatment should be started and supervised by a doctor experienced in the use of cancer medicines.

Before treatment starts, the doctor will carry out tests to check whether the cancer cells have mutations in genes for IDH1 and IDH2.

Voranigo is available as tablets which the patient should take once a day by mouth at about the same time each day. The patient should not eat at least 2 hours before and 1 hour after taking Voranigo. Treatment lasts for as long as the patient benefits from it and does not have intolerable side effects.

For more information about using Voranigo, see the package leaflet or contact your doctor or pharmacist.

## How does Voranigo work?

In patients with astrocytoma or oligodendroglioma who have mutations in the genes for the IDH1 and IDH2 protein, these proteins do not work properly, causing the production of high levels of a substance called 2-hydroxyglutarate (2-HG).

2-HG causes changes in the way cells grow and mature, leading to the development of tumours. The active substance in Voranigo, vorasidenib, blocks the activity of the abnormal IDH1 and IDH2 proteins, thereby reducing levels of 2-HG. This allows the cells to grow and mature normally, preventing the tumour from growing.

## What benefits of Voranigo have been shown in studies?

A main study involved 331 patients with grade 2 oligodendroglioma or astrocytoma with an IDH1 or IDH2 mutation and who had undergone surgery at least once to remove the tumour. The results showed that Voranigo was effective at preventing the disease from getting worse. In this study patients who had Voranigo lived for around 28 months without the disease getting worse, while those who had a placebo (a dummy treatment) lived for around 11 months without their disease worsening.

## What are the risks associated with Voranigo?

For the full list of side effects and restrictions with Voranigo, see the package leaflet.

The most common side effects with Voranigo (which may affect more than 1 in 10 people) include raised levels of liver enzymes, tiredness and diarrhoea.

Some side effects can be serious. The most frequent (which may affect up to 1 in 10 people) include raised levels of liver enzymes.

## Why is Voranigo authorised in the EU?

Voranigo is effective at slowing the worsening of low-grade astrocytoma or oligodendroglioma. The medicine can therefore help patients avoid aggressive treatments, such as chemotherapy or radiotherapy. The main side effects are related to liver problems, but most side effects in the main study were not considered serious. The known side effects are considered manageable and more information about the safety of the medicine will come from future studies.

The European Medicines Agency therefore decided that Voranigo's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Voranigo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Voranigo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Voranigo are continuously monitored. Suspected side effects reported with Voranigo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Voranigo

Voranigo received a marketing authorisation valid throughout the EU on 17 September 2025.

Voranigo : EPAR - Medicine overview

Reference Number: EMA/287300/2025

English (EN) (95.21 KB - PDF)

**First published:** 26/09/2025

[View](/en/documents/overview/voranigo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-238)

български (BG) (117.77 KB - PDF)

**First published:**

26/09/2025

[View](/bg/documents/overview/voranigo-epar-medicine-overview_bg.pdf)

español (ES) (92.94 KB - PDF)

**First published:**

26/09/2025

[View](/es/documents/overview/voranigo-epar-medicine-overview_es.pdf)

čeština (CS) (114.44 KB - PDF)

**First published:**

26/09/2025

[View](/cs/documents/overview/voranigo-epar-medicine-overview_cs.pdf)

dansk (DA) (93.58 KB - PDF)

**First published:**

26/09/2025

[View](/da/documents/overview/voranigo-epar-medicine-overview_da.pdf)

Deutsch (DE) (97.4 KB - PDF)

**First published:**

26/09/2025

[View](/de/documents/overview/voranigo-epar-medicine-overview_de.pdf)

eesti keel (ET) (90.8 KB - PDF)

**First published:**

26/09/2025

[View](/et/documents/overview/voranigo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (117.13 KB - PDF)

**First published:**

26/09/2025

[View](/el/documents/overview/voranigo-epar-medicine-overview_el.pdf)

français (FR) (93.61 KB - PDF)

**First published:**

26/09/2025

[View](/fr/documents/overview/voranigo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (113.21 KB - PDF)

**First published:**

26/09/2025

[View](/hr/documents/overview/voranigo-epar-medicine-overview_hr.pdf)

italiano (IT) (91.98 KB - PDF)

**First published:**

26/09/2025

[View](/it/documents/overview/voranigo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (131.97 KB - PDF)

**First published:**

26/09/2025

[View](/lv/documents/overview/voranigo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (114.02 KB - PDF)

**First published:**

26/09/2025

[View](/lt/documents/overview/voranigo-epar-medicine-overview_lt.pdf)

magyar (HU) (114.41 KB - PDF)

**First published:**

26/09/2025

[View](/hu/documents/overview/voranigo-epar-medicine-overview_hu.pdf)

Malti (MT) (125.58 KB - PDF)

**First published:**

26/09/2025

[View](/mt/documents/overview/voranigo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (93.75 KB - PDF)

**First published:**

26/09/2025

[View](/nl/documents/overview/voranigo-epar-medicine-overview_nl.pdf)

polski (PL) (117.09 KB - PDF)

**First published:**

26/09/2025

[View](/pl/documents/overview/voranigo-epar-medicine-overview_pl.pdf)

português (PT) (93.82 KB - PDF)

**First published:**

26/09/2025

[View](/pt/documents/overview/voranigo-epar-medicine-overview_pt.pdf)

română (RO) (112.47 KB - PDF)

**First published:**

26/09/2025

[View](/ro/documents/overview/voranigo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (114.37 KB - PDF)

**First published:**

26/09/2025

[View](/sk/documents/overview/voranigo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (111.84 KB - PDF)

**First published:**

26/09/2025

[View](/sl/documents/overview/voranigo-epar-medicine-overview_sl.pdf)

Suomi (FI) (91.15 KB - PDF)

**First published:**

26/09/2025

[View](/fi/documents/overview/voranigo-epar-medicine-overview_fi.pdf)

svenska (SV) (91.52 KB - PDF)

**First published:**

26/09/2025

[View](/sv/documents/overview/voranigo-epar-medicine-overview_sv.pdf)

Voranigo : EPAR - Risk management plan

English (EN) (2.04 MB - PDF)

**First published:** 26/09/2025

**Last updated:** 12/11/2025

[View](/en/documents/rmp/voranigo-epar-risk-management-plan_en.pdf)

## Product information

Voranigo : EPAR - Product information

English (EN) (445.38 KB - PDF)

**First published:** 26/09/2025

[View](/en/documents/product-information/voranigo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-999)

български (BG) (559.53 KB - PDF)

**First published:**

26/09/2025

[View](/bg/documents/product-information/voranigo-epar-product-information_bg.pdf)

español (ES) (419.62 KB - PDF)

**First published:**

26/09/2025

[View](/es/documents/product-information/vorangio-epar-product-information_es.pdf)

čeština (CS) (527.82 KB - PDF)

**First published:**

26/09/2025

[View](/cs/documents/product-information/voranigo-epar-product-information_cs.pdf)

dansk (DA) (293.87 KB - PDF)

**First published:**

26/09/2025

[View](/da/documents/product-information/voranigo-epar-product-information_da.pdf)

Deutsch (DE) (459.14 KB - PDF)

**First published:**

26/09/2025

[View](/de/documents/product-information/voranigo-epar-product-information_de.pdf)

eesti keel (ET) (558.93 KB - PDF)

**First published:**

26/09/2025

[View](/et/documents/product-information/voranigo-epar-product-information_et.pdf)

ελληνικά (EL) (720.44 KB - PDF)

**First published:**

26/09/2025

[View](/el/documents/product-information/voranigo-epar-product-information_el.pdf)

français (FR) (430.93 KB - PDF)

**First published:**

26/09/2025

[View](/fr/documents/product-information/vorangio-epar-product-information_fr.pdf)

hrvatski (HR) (657.97 KB - PDF)

**First published:**

26/09/2025

[View](/hr/documents/product-information/vorangio-epar-product-information_hr.pdf)

íslenska (IS) (491.37 KB - PDF)

**First published:**

26/09/2025

[View](/is/documents/product-information/vorangio-epar-product-information_is.pdf)

italiano (IT) (445.82 KB - PDF)

**First published:**

26/09/2025

[View](/it/documents/product-information/voranigo-epar-product-information_it.pdf)

latviešu valoda (LV) (540.44 KB - PDF)

**First published:**

26/09/2025

[View](/lv/documents/product-information/voranigo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (545.38 KB - PDF)

**First published:**

26/09/2025

[View](/lt/documents/product-information/voranigo-epar-product-information_lt.pdf)

magyar (HU) (587.51 KB - PDF)

**First published:**

26/09/2025

[View](/hu/documents/product-information/voranigo-epar-product-information_hu.pdf)

Malti (MT) (394.38 KB - PDF)

**First published:**

26/09/2025

[View](/mt/documents/product-information/voranigo-epar-product-information_mt.pdf)

Nederlands (NL) (306.53 KB - PDF)

**First published:**

26/09/2025

[View](/nl/documents/product-information/voranigo-epar-product-information_nl.pdf)

norsk (NO) (285.05 KB - PDF)

**First published:**

26/09/2025

[View](/no/documents/product-information/voranigo-epar-product-information_no.pdf)

polski (PL) (566.29 KB - PDF)

**First published:**

26/09/2025

[View](/pl/documents/product-information/voranigo-epar-product-information_pl.pdf)

português (PT) (554.29 KB - PDF)

**First published:**

26/09/2025

[View](/pt/documents/product-information/voranigo-epar-product-information_pt.pdf)

română (RO) (592.97 KB - PDF)

**First published:**

26/09/2025

[View](/ro/documents/product-information/voranigo-epar-product-information_ro.pdf)

slovenčina (SK) (967.05 KB - PDF)

**First published:**

26/09/2025

[View](/sk/documents/product-information/voranigo-epar-product-information_sk.pdf)

slovenščina (SL) (571.58 KB - PDF)

**First published:**

26/09/2025

[View](/sl/documents/product-information/voranigo-epar-product-information_sl.pdf)

Suomi (FI) (298.79 KB - PDF)

**First published:**

26/09/2025

[View](/fi/documents/product-information/voranigo-epar-product-information_fi.pdf)

svenska (SV) (283.68 KB - PDF)

**First published:**

26/09/2025

[View](/sv/documents/product-information/voranigo-epar-product-information_sv.pdf)

17/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Voranigo : EPAR - All authorised presentations

English (EN) (49.23 KB - PDF)

**First published:** 26/09/2025

[View](/en/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-214)

български (BG) (66.96 KB - PDF)

**First published:**

26/09/2025

[View](/bg/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.28 KB - PDF)

**First published:**

26/09/2025

[View](/es/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (90.5 KB - PDF)

**First published:**

26/09/2025

[View](/cs/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (41.11 KB - PDF)

**First published:**

26/09/2025

[View](/da/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (75.42 KB - PDF)

**First published:**

26/09/2025

[View](/de/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (52.41 KB - PDF)

**First published:**

26/09/2025

[View](/et/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (60.95 KB - PDF)

**First published:**

26/09/2025

[View](/el/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_el.pdf)

français (FR) (45.98 KB - PDF)

**First published:**

26/09/2025

[View](/fr/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (63.17 KB - PDF)

**First published:**

26/09/2025

[View](/hr/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (42.96 KB - PDF)

**First published:**

26/09/2025

[View](/is/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (74.26 KB - PDF)

**First published:**

26/09/2025

[View](/it/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (58.94 KB - PDF)

**First published:**

26/09/2025

[View](/lv/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (60.63 KB - PDF)

**First published:**

26/09/2025

[View](/lt/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (51.14 KB - PDF)

**First published:**

26/09/2025

[View](/hu/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (68.29 KB - PDF)

**First published:**

26/09/2025

[View](/mt/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (51.12 KB - PDF)

**First published:**

26/09/2025

[View](/nl/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.48 KB - PDF)

**First published:**

26/09/2025

[View](/no/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_no.pdf)

polski (PL) (52.63 KB - PDF)

**First published:**

26/09/2025

[View](/pl/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.58 KB - PDF)

**First published:**

26/09/2025

[View](/pt/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_pt.pdf)

română (RO) (89.56 KB - PDF)

**First published:**

26/09/2025

[View](/ro/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (58.92 KB - PDF)

**First published:**

26/09/2025

[View](/sk/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (68.23 KB - PDF)

**First published:**

26/09/2025

[View](/sl/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (51.36 KB - PDF)

**First published:**

26/09/2025

[View](/fi/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.76 KB - PDF)

**First published:**

26/09/2025

[View](/sv/documents/all-authorised-presentations/voranigo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Voranigo Active substance vorasidenib International non-proprietary name (INN) or common name vorasidenib Therapeutic area (MeSH)

- Oligodendroglioma
- Astrocytoma

Anatomical therapeutic chemical (ATC) code L01XM04

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Voranigo as monotherapy is indicated for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/006284

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Les Laboratoires Servier

50 rue Carnot

Opinion adopted 24/07/2025 Marketing authorisation issued 17/09/2025

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Voranigo : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

English (EN) (119.74 KB - PDF)

**First published:** 26/09/2025

[View](/en/documents/pip-compliance/voranigo-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

## Initial marketing authorisation documents

Voranigo : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000159477

English (EN) (279.59 KB - PDF)

**First published:** 26/09/2025

[View](/en/documents/orphan-maintenance-report/voranigo-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Voranigo : EPAR - Public assessment report

Adopted

Reference Number: EMA/271829/2025

English (EN) (3.38 MB - PDF)

**First published:** 26/09/2025

[View](/en/documents/assessment-report/voranigo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Voranigo

Adopted

Reference Number: EMA/CHMP/227935/2025

English (EN) (162.11 KB - PDF)

**First published:** 25/07/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-voranigo_en.pdf)

#### News on Voranigo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025) 25/07/2025

#### More information on Voranigo

- [EU/3/22/2737 - orphan designation for treatment of glioma](/en/medicines/human/orphan-designations/eu-3-22-2737)

**This page was last updated on** 26/09/2025

## Share this page

[Back to top](#main-content)